TWI324604B
(en)
*
|
2003-06-18 |
2010-05-11 |
Novartis Ag |
New use of staurosporine derivatives
|
WO2005011598A2
(en)
*
|
2003-07-31 |
2005-02-10 |
University Of South Florida |
Leukemia treatment method and composition
|
EP1653973A1
(en)
*
|
2003-08-08 |
2006-05-10 |
Novartis AG |
Combinations comprising staurosporines
|
US20080221080A1
(en)
*
|
2003-08-25 |
2008-09-11 |
James Douglas Griffin |
Method of Treating Mixed Lineage Leukemia Gene-Rearranged Acute Lymphoblastic Leukemias
|
US7750160B2
(en)
|
2003-11-13 |
2010-07-06 |
Ambit Biosciences Corporation |
Isoxazolyl urea derivatives as kinase modulators
|
WO2005053704A1
(en)
*
|
2003-12-01 |
2005-06-16 |
Novartis Ag |
Method for predicting drug responsiveness in myeloid neoplasms
|
EP1699477A2
(en)
*
|
2003-12-11 |
2006-09-13 |
Theravance, Inc. |
Compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
|
WO2006020145A2
(en)
*
|
2004-07-19 |
2006-02-23 |
The Johns Hopkins University |
Flt3 inhibitors for immune suppression
|
GB0419159D0
(en)
*
|
2004-08-27 |
2004-09-29 |
Novartis Ag |
Organic compounds
|
AU2005309019A1
(en)
*
|
2004-11-24 |
2006-06-01 |
Novartis Ag |
Combinations of JAK inhibitors and at least one of Bcr-Abl, Flt-3, FAK or RAF kinase inhibitors
|
GB0426821D0
(en)
*
|
2004-12-07 |
2005-01-12 |
Novartis Ag |
Organic compounds
|
AU2006244068B9
(en)
|
2005-05-10 |
2012-10-25 |
Incyte Holdings Corporation |
Modulators of indoleamine 2,3-dioxygenase and methods of using the same
|
US7825244B2
(en)
|
2005-06-10 |
2010-11-02 |
Janssen Pharmaceutica Nv |
Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis
|
US8071768B2
(en)
|
2005-06-10 |
2011-12-06 |
Janssen Pharmaceutica, N.V. |
Alkylquinoline and alkylquinazoline kinase modulators
|
US20060281788A1
(en)
|
2005-06-10 |
2006-12-14 |
Baumann Christian A |
Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
|
RU2008105832A
(ru)
*
|
2005-07-20 |
2009-08-27 |
Новартис АГ (CH) |
Органические соединения
|
EP1926735A1
(en)
|
2005-09-22 |
2008-06-04 |
Incyte Corporation |
Tetracyclic inhibitors of janus kinases
|
CA2626623C
(en)
|
2005-10-18 |
2016-08-30 |
Janssen Pharmaceutica N.V. |
Method of inhibiting flt3 kinase
|
GB0522932D0
(en)
*
|
2005-11-10 |
2005-12-21 |
Univ Southampton |
PKC412 in treatment of atypical chronic myeloid leukemia
|
US7973032B2
(en)
|
2005-11-14 |
2011-07-05 |
University Of Zurich |
Staurosporine derivatives for use in alveolar rhabdomyosarcoma
|
MY162590A
(en)
|
2005-12-13 |
2017-06-30 |
Incyte Holdings Corp |
Heteroaryl substituted pyrrolo[2,3-b] pyridines and pyrrolo[2,3-b] pyrimidines as janus kinase inhibitors
|
JP5331681B2
(ja)
|
2006-04-20 |
2013-10-30 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
c−fmsキナーゼの阻害剤
|
MX2008013533A
(es)
|
2006-04-20 |
2009-01-15 |
Janssen Pharmaceutica Nv |
Compuestos heterociclicos como inhibidores de c-fms cinasa.
|
US8697716B2
(en)
|
2006-04-20 |
2014-04-15 |
Janssen Pharmaceutica Nv |
Method of inhibiting C-KIT kinase
|
GB0612542D0
(en)
*
|
2006-06-23 |
2006-08-02 |
Novartis Ag |
Combinations comprising staurosporines
|
US8513270B2
(en)
|
2006-12-22 |
2013-08-20 |
Incyte Corporation |
Substituted heterocycles as Janus kinase inhibitors
|
CL2008001709A1
(es)
|
2007-06-13 |
2008-11-03 |
Incyte Corp |
Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
|
EP3495369B1
(en)
|
2007-06-13 |
2021-10-27 |
Incyte Holdings Corporation |
Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile
|
JO3240B1
(ar)
|
2007-10-17 |
2018-03-08 |
Janssen Pharmaceutica Nv |
c-fms مثبطات كيناز
|
CA2704599C
(en)
|
2007-11-16 |
2015-05-12 |
Incyte Corporation |
4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
|
SI2288610T1
(sl)
|
2008-03-11 |
2016-11-30 |
Incyte Holdings Corporation |
Derivati azetidina in ciklobutana kot inhibitorji jak
|
CA2722326A1
(en)
|
2008-04-24 |
2009-10-29 |
Incyte Corporation |
Macrocyclic compounds and their use as kinase inhibitors
|
KR101783004B1
(ko)
|
2008-07-08 |
2017-09-28 |
인사이트 홀딩스 코포레이션 |
인돌아민 2,3-디옥시게나아제의 억제제로서의 1,2,5-옥사디아졸
|
CL2009001884A1
(es)
|
2008-10-02 |
2010-05-14 |
Incyte Holdings Corp |
Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
|
WO2010085597A1
(en)
|
2009-01-23 |
2010-07-29 |
Incyte Corporation |
Macrocyclic compounds and their use as kinase inhibitors
|
MX2011012262A
(es)
|
2009-05-22 |
2012-01-25 |
Incyte Corp |
3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il] octano-o heptano-nitrilo como inhibidores de cinasas janus (jak).
|
EA025520B1
(ru)
|
2009-05-22 |
2017-01-30 |
Инсайт Холдингс Корпорейшн |
N-(ГЕТЕРО)АРИЛПИРРОЛИДИНОВЫЕ ПРОИЗВОДНЫЕ ПИРАЗОЛ-4-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ И ПИРРОЛ-3-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ
|
AR077280A1
(es)
|
2009-06-29 |
2011-08-17 |
Incyte Corp |
Pirimidinonas como inhibidores de pi3k, y composiciones farmaceuticas que los comprenden
|
TW201113285A
(en)
|
2009-09-01 |
2011-04-16 |
Incyte Corp |
Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
PT2486041E
(pt)
|
2009-10-09 |
2013-11-14 |
Incyte Corp |
Derivados hidroxilo, ceto e glucuronido de 3-(4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)-3-ciclopentil-propanonitrilo
|
EP2327706A1
(en)
*
|
2009-11-30 |
2011-06-01 |
Novartis AG |
Polymorphous forms III and IV of N-benzoyl-staurosporine
|
WO2011075630A1
(en)
|
2009-12-18 |
2011-06-23 |
Incyte Corporation |
Substituted fused aryl and heteroaryl derivatives as pi3k inhibitors
|
WO2011075643A1
(en)
|
2009-12-18 |
2011-06-23 |
Incyte Corporation |
Substituted heteroaryl fused derivatives as pi3k inhibitors
|
EP2521782B1
(en)
|
2010-01-05 |
2019-04-10 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Flt3 receptor antagonists for the treatment or the prevention of pain disorders
|
SG182480A1
(en)
|
2010-01-12 |
2012-08-30 |
Ab Science |
Thiazole and oxazole kinase inhibitors
|
EA023444B1
(ru)
|
2010-02-18 |
2016-06-30 |
Инсайт Холдингс Корпорейшн |
Циклобутановые и метилциклобутановые производные, композиции на их основе и способы их применения
|
SI3354652T1
(sl)
|
2010-03-10 |
2020-08-31 |
Incyte Holdings Corporation |
Derivati piperidin-4-il azetidina kot inhibitorji JAK1
|
EP2558463A1
(en)
|
2010-04-14 |
2013-02-20 |
Incyte Corporation |
Fused derivatives as i3 inhibitors
|
SG10201910912TA
(en)
|
2010-05-21 |
2020-01-30 |
Incyte Corp |
Topical Formulation for a JAK Inhibitor
|
US9062055B2
(en)
|
2010-06-21 |
2015-06-23 |
Incyte Corporation |
Fused pyrrole derivatives as PI3K inhibitors
|
BR112013012502A2
(pt)
|
2010-11-19 |
2019-03-06 |
Incyte Corporation |
pirrolopiridina ciclobutil substituída e derivados de pirrolopirimidina derivativos como inibidores de jak
|
US9034884B2
(en)
|
2010-11-19 |
2015-05-19 |
Incyte Corporation |
Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
|
TW201249844A
(en)
|
2010-12-20 |
2012-12-16 |
Incyte Corp |
N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors
|
WO2012112847A1
(en)
|
2011-02-18 |
2012-08-23 |
Novartis Pharma Ag |
mTOR/JAK INHIBITOR COMBINATION THERAPY
|
WO2012125629A1
(en)
|
2011-03-14 |
2012-09-20 |
Incyte Corporation |
Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
|
WO2012135009A1
(en)
|
2011-03-25 |
2012-10-04 |
Incyte Corporation |
Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
|
MY165963A
(en)
|
2011-06-20 |
2018-05-18 |
Incyte Holdings Corp |
Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
|
EP2741747A1
(en)
|
2011-08-10 |
2014-06-18 |
Novartis Pharma AG |
JAK P13K/mTOR COMBINATION THERAPY
|
TW201313721A
(zh)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
作為jak抑制劑之環己基氮雜環丁烷衍生物
|
SI2751109T1
(sl)
|
2011-09-02 |
2017-03-31 |
Incyte Holdings Corporation |
Heterociklilamini kot inhibitorji pi3k
|
UA111854C2
(uk)
|
2011-09-07 |
2016-06-24 |
Інсайт Холдінгс Корпорейшн |
Способи і проміжні сполуки для отримання інгібіторів jak
|
AR090548A1
(es)
|
2012-04-02 |
2014-11-19 |
Incyte Corp |
Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
|
CA2871337C
(en)
*
|
2012-04-24 |
2021-04-20 |
International Stem Cell Corporation |
Derivation of neural stem cells and dopaminergic neurons from human pluripotent stem cells
|
US9193733B2
(en)
|
2012-05-18 |
2015-11-24 |
Incyte Holdings Corporation |
Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
|
PT3176170T
(pt)
|
2012-06-13 |
2019-02-05 |
Incyte Holdings Corp |
Compostos tricíclicos substituídos como inibidores de fgfr
|
EP2882757B1
(en)
|
2012-08-07 |
2016-10-05 |
Janssen Pharmaceutica, N.V. |
Process for the preparation of heterocyclic ester derivatives
|
JOP20180012A1
(ar)
|
2012-08-07 |
2019-01-30 |
Janssen Pharmaceutica Nv |
عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
|
JP6407504B2
(ja)
|
2012-09-21 |
2018-10-17 |
アログ・ファーマシューティカルズ・インコーポレイテッドArog Pharmaceuticals,Inc. |
恒常的に活性であるリン酸化型flt3キナーゼの阻害方法
|
SG10201703533VA
(en)
|
2012-11-01 |
2017-06-29 |
Incyte Corp |
Tricyclic fused thiophene derivatives as jak inhibitors
|
SG11201503695XA
(en)
|
2012-11-15 |
2015-06-29 |
Incyte Corp |
Sustained-release dosage forms of ruxolitinib
|
BR112015016282A2
(pt)
|
2013-01-07 |
2017-07-11 |
Arog Pharmaceuticals Inc |
crenolanibe para tratamento de distúrbios proliferativos de flt3 mutado
|
TWI657090B
(zh)
|
2013-03-01 |
2019-04-21 |
英塞特控股公司 |
吡唑并嘧啶衍生物治療PI3Kδ 相關病症之用途
|
EA030705B1
(ru)
|
2013-03-06 |
2018-09-28 |
Инсайт Холдингс Корпорейшн |
Способы и промежуточные соединения при получении ингибитора jak
|
PE20152033A1
(es)
|
2013-04-19 |
2016-01-21 |
Incyte Holdings Corp |
Heterociclos bicicliclos como inhibidores de fgfr
|
PE20160126A1
(es)
|
2013-05-17 |
2016-02-24 |
Incyte Corp |
Derivados del bipirazol como inhibidores jak
|
ES2792549T3
(es)
|
2013-08-07 |
2020-11-11 |
Incyte Corp |
Formas de dosificación de liberación sostenida para un inhibidor de JAK1
|
CN105555313A
(zh)
|
2013-08-20 |
2016-05-04 |
因赛特公司 |
在c-反应蛋白水平较高的实体肿瘤患者中的存活益处
|
US10463658B2
(en)
|
2013-10-25 |
2019-11-05 |
Videra Pharmaceuticals, Llc |
Method of inhibiting FLT3 kinase
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
CN106456773A
(zh)
|
2014-02-28 |
2017-02-22 |
因赛特公司 |
用于治疗骨髓增生异常综合征的jak1抑制剂
|
CN106103484B
(zh)
|
2014-03-14 |
2021-08-20 |
诺华股份有限公司 |
针对lag-3的抗体分子及其用途
|
KR20220066179A
(ko)
|
2014-04-08 |
2022-05-23 |
인사이트 코포레이션 |
Jak 및 pi3k 억제제 조합에 의한 b-세포 악성종양의 치료
|
AU2015253192B2
(en)
|
2014-04-30 |
2019-05-16 |
Incyte Holdings Corporation |
Processes of preparing a JAK1 inhibitor and new forms thereto
|
WO2015184305A1
(en)
|
2014-05-30 |
2015-12-03 |
Incyte Corporation |
TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
|
WO2015191677A1
(en)
|
2014-06-11 |
2015-12-17 |
Incyte Corporation |
Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
|
US10065937B2
(en)
|
2014-07-31 |
2018-09-04 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
FLT3 receptor antagonists
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
CU20170052A7
(es)
|
2014-10-14 |
2017-11-07 |
Dana Farber Cancer Inst Inc |
Moléculas de anticuerpo que se unen a pd-l1
|
EP3233918A1
(en)
|
2014-12-19 |
2017-10-25 |
Novartis AG |
Combination therapies
|
WO2016130501A1
(en)
|
2015-02-09 |
2016-08-18 |
Incyte Corporation |
Aza-heteroaryl compounds as pi3k-gamma inhibitors
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
EP3617205B1
(en)
|
2015-02-20 |
2021-08-04 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
CN117800973A
(zh)
|
2015-02-27 |
2024-04-02 |
因赛特控股公司 |
Pi3k抑制剂的盐及其制备方法
|
MY190404A
(en)
|
2015-03-10 |
2022-04-21 |
Aduro Biotech Inc |
Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
|
US20160362424A1
(en)
|
2015-05-11 |
2016-12-15 |
Incyte Corporation |
Salts of (s)-7-(1-(9h-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5h-thiazolo[3,2-a]pyrimidin-5-one
|
US9988401B2
(en)
|
2015-05-11 |
2018-06-05 |
Incyte Corporation |
Crystalline forms of a PI3K inhibitor
|
WO2016183060A1
(en)
|
2015-05-11 |
2016-11-17 |
Incyte Corporation |
Process for the synthesis of a phosphoinositide 3-kinase inhibitor
|
SI3317301T1
(sl)
|
2015-07-29 |
2021-10-29 |
Novartis Ag |
Kombinirane terapije, ki obsegajo molekule protitelesa na LAG-3
|
EP3316902A1
(en)
|
2015-07-29 |
2018-05-09 |
Novartis AG |
Combination therapies comprising antibody molecules to tim-3
|
BR112018008904A2
(pt)
|
2015-11-03 |
2018-11-27 |
Janssen Biotech Inc |
anticorpos que se ligam especificamente a tim-3 e seus usos
|
TWI744256B
(zh)
|
2015-11-06 |
2021-11-01 |
美商英塞特公司 |
作為PI3K-γ抑制劑之雜環化合物
|
CA3007671A1
(en)
|
2015-12-17 |
2017-06-22 |
Novartis Ag |
Antibody molecules to pd-1 and uses thereof
|
ES2833955T3
(es)
|
2016-01-05 |
2021-06-16 |
Incyte Corp |
Piridinas sustituidas con pirazol/imidazol como inhibidores de PI3K-Gamma
|
CN110218206B
(zh)
*
|
2016-06-01 |
2022-03-04 |
中国海洋大学 |
双吲哚马来酰亚胺衍生物及其制备方法和用途
|
EP3254698A1
(en)
|
2016-06-08 |
2017-12-13 |
Universite De Montpellier |
Flt3 receptor inhibitor at low dosage for the treatment of neuropathic pain
|
WO2017223414A1
(en)
|
2016-06-24 |
2017-12-28 |
Incyte Corporation |
HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS
|
EP3507367A4
(en)
|
2016-07-05 |
2020-03-25 |
Aduro BioTech, Inc. |
CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
|
WO2018085292A1
(en)
|
2016-11-02 |
2018-05-11 |
Arog Pharmaceuticals, Inc. |
Crenolanib for treating flt3 mutated proliferative disorders associated mutations
|
UY37695A
(es)
|
2017-04-28 |
2018-11-30 |
Novartis Ag |
Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
|
WO2018211018A1
(en)
|
2017-05-17 |
2018-11-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Flt3 inhibitors for improving pain treatments by opioids
|
US11331313B2
(en)
|
2017-05-22 |
2022-05-17 |
Whitehead Institute For Biomedical Research |
KCC2 expression enhancing compounds and uses thereof
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
CN107417743B
(zh)
*
|
2017-06-15 |
2020-07-21 |
杭州科兴生物化工有限公司 |
星孢菌素醛基取代衍生物及其制备方法和应用
|
WO2018237173A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES
|
WO2019057649A1
(en)
|
2017-09-19 |
2019-03-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA
|
SG11202003428VA
(en)
|
2017-10-18 |
2020-05-28 |
Incyte Corp |
Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors
|
US10596161B2
(en)
|
2017-12-08 |
2020-03-24 |
Incyte Corporation |
Low dose combination therapy for treatment of myeloproliferative neoplasms
|
US11306079B2
(en)
|
2017-12-21 |
2022-04-19 |
Incyte Corporation |
3-(5-amino-pyrazin-2-yl)-benzenesulfonamide derivatives and related compounds as PI3K-gamma kinase inhibitors
|
PL3746429T3
(pl)
|
2018-01-30 |
2022-06-20 |
Incyte Corporation |
Procesy do otrzymywania (1-(3-fluoro-2-(trifluorometylo)izonikotynoilo)piperydyn-4-onu)
|
SG11202007805SA
(en)
|
2018-02-16 |
2020-09-29 |
Incyte Corp |
Jak1 pathway inhibitors for the treatment of cytokine-related disorders
|
PE20211001A1
(es)
|
2018-02-27 |
2021-06-01 |
Incyte Corp |
Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b
|
ES2910071T3
(es)
|
2018-03-08 |
2022-05-11 |
Incyte Corp |
Compuestos de aminopirazina diol como inhibidores de PI3K-Y
|
US11584961B2
(en)
|
2018-03-30 |
2023-02-21 |
Incyte Corporation |
Biomarkers for inflammatory skin disease
|
WO2019191684A1
(en)
|
2018-03-30 |
2019-10-03 |
Incyte Corporation |
Treatment of hidradenitis suppurativa using jak inhibitors
|
US11220510B2
(en)
|
2018-04-09 |
2022-01-11 |
Incyte Corporation |
Pyrrole tricyclic compounds as A2A / A2B inhibitors
|
CN112867716A
(zh)
|
2018-05-04 |
2021-05-28 |
因赛特公司 |
Fgfr抑制剂的固体形式和其制备方法
|
CA3099116A1
(en)
|
2018-05-04 |
2019-11-07 |
Incyte Corporation |
Salts of an fgfr inhibitor
|
JP7391046B2
(ja)
|
2018-05-18 |
2023-12-04 |
インサイト・コーポレイション |
A2a/a2b阻害剤としての縮合ピリミジン誘導体
|
WO2019227007A1
(en)
|
2018-05-25 |
2019-11-28 |
Incyte Corporation |
Tricyclic heterocyclic compounds as sting activators
|
TW202015726A
(zh)
|
2018-05-30 |
2020-05-01 |
瑞士商諾華公司 |
Entpd2抗體、組合療法、及使用該等抗體和組合療法之方法
|
WO2020010003A1
(en)
|
2018-07-02 |
2020-01-09 |
Incyte Corporation |
AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
|
GEP20237560B
(en)
|
2018-07-05 |
2023-10-25 |
Incyte Corp |
Fused pyrazine derivatives as a2a / a2b inhibitors
|
WO2020028565A1
(en)
|
2018-07-31 |
2020-02-06 |
Incyte Corporation |
Tricyclic heteraryl compounds as sting activators
|
US10875872B2
(en)
|
2018-07-31 |
2020-12-29 |
Incyte Corporation |
Heteroaryl amide compounds as sting activators
|
CR20210165A
(es)
|
2018-09-05 |
2021-10-01 |
Incyte Corp |
Formas cristalinas de un inhibidor de fosfoinositida 3-quinasa (pi3k) campo técnico
|
US11066404B2
(en)
|
2018-10-11 |
2021-07-20 |
Incyte Corporation |
Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
|
CA3118330A1
(en)
|
2018-11-01 |
2020-05-07 |
Syros Pharmaceuticals, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
US11396502B2
(en)
|
2018-11-13 |
2022-07-26 |
Incyte Corporation |
Substituted heterocyclic derivatives as PI3K inhibitors
|
US11161838B2
(en)
|
2018-11-13 |
2021-11-02 |
Incyte Corporation |
Heterocyclic derivatives as PI3K inhibitors
|
WO2020102198A1
(en)
|
2018-11-13 |
2020-05-22 |
Incyte Corporation |
Heterocyclic derivatives as pi3k inhibitors
|
US11596692B1
(en)
|
2018-11-21 |
2023-03-07 |
Incyte Corporation |
PD-L1/STING conjugates and methods of use
|
BR112021011894A2
(pt)
|
2018-12-21 |
2021-09-08 |
Daiichi Sankyo Company, Limited |
Composição farmacêutica
|
WO2020146237A1
(en)
|
2019-01-07 |
2020-07-16 |
Incyte Corporation |
Heteroaryl amide compounds as sting activators
|
TWI829857B
(zh)
|
2019-01-29 |
2024-01-21 |
美商英塞特公司 |
作為a2a / a2b抑制劑之吡唑并吡啶及***并吡啶
|
WO2020168197A1
(en)
|
2019-02-15 |
2020-08-20 |
Incyte Corporation |
Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
|
KR20210139269A
(ko)
|
2019-02-15 |
2021-11-22 |
인사이트 코포레이션 |
사이클린-의존성 키나아제 2 바이오마커 및 이들의 용도
|
WO2020180959A1
(en)
|
2019-03-05 |
2020-09-10 |
Incyte Corporation |
Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
|
WO2020185532A1
(en)
|
2019-03-08 |
2020-09-17 |
Incyte Corporation |
Methods of treating cancer with an fgfr inhibitor
|
US11919904B2
(en)
|
2019-03-29 |
2024-03-05 |
Incyte Corporation |
Sulfonylamide compounds as CDK2 inhibitors
|
US11447494B2
(en)
|
2019-05-01 |
2022-09-20 |
Incyte Corporation |
Tricyclic amine compounds as CDK2 inhibitors
|
WO2020223469A1
(en)
|
2019-05-01 |
2020-11-05 |
Incyte Corporation |
N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
|
CA3150975A1
(en)
|
2019-06-10 |
2020-12-17 |
Incyte Corporation |
Topical treatment of vitiligo by a jak inhibitor
|
WO2021007269A1
(en)
|
2019-07-09 |
2021-01-14 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
MX2022001133A
(es)
|
2019-08-01 |
2022-04-25 |
Incyte Corp |
Regimen de dosificacion para un inhibidor de indolamina 2,3-dioxigenasa (ido).
|
CN116348458A
(zh)
|
2019-08-14 |
2023-06-27 |
因赛特公司 |
作为cdk2抑制剂的咪唑基嘧啶基胺化合物
|
AU2020337350A1
(en)
|
2019-08-26 |
2022-03-10 |
Incyte Corporation |
Triazolopyrimidines as A2A / A2B inhibitors
|
US11839619B2
(en)
|
2019-09-16 |
2023-12-12 |
The Regents Of The University Of California |
Methods for treatment of pediatric systemic mastocytosis
|
JP2022548881A
(ja)
|
2019-09-18 |
2022-11-22 |
ノバルティス アーゲー |
Entpd2抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
|
US11851426B2
(en)
|
2019-10-11 |
2023-12-26 |
Incyte Corporation |
Bicyclic amines as CDK2 inhibitors
|
JOP20220083A1
(ar)
|
2019-10-14 |
2023-01-30 |
Incyte Corp |
حلقات غير متجانسة ثنائية الحلقة كمثبطات لـ fgfr
|
JP2023506118A
(ja)
|
2019-10-16 |
2023-02-15 |
インサイト・コーポレイション |
皮膚エリテマトーデス及び扁平苔癬(lp)の治療のためのjak1阻害剤の使用
|
US11566028B2
(en)
|
2019-10-16 |
2023-01-31 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
CA3163875A1
(en)
|
2019-12-04 |
2021-06-10 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
CA3162010A1
(en)
|
2019-12-04 |
2021-06-10 |
Incyte Corporation |
Derivatives of an fgfr inhibitor
|
IL296065A
(en)
|
2020-03-06 |
2022-10-01 |
Incyte Corp |
Combined treatment including axl/mer and pd-1/pd-l1 inhibitors
|
EP4135844A1
(en)
|
2020-04-16 |
2023-02-22 |
Incyte Corporation |
Fused tricyclic kras inhibitors
|
US11739102B2
(en)
|
2020-05-13 |
2023-08-29 |
Incyte Corporation |
Fused pyrimidine compounds as KRAS inhibitors
|
US11685731B2
(en)
|
2020-06-02 |
2023-06-27 |
Incyte Corporation |
Processes of preparing a JAK1 inhibitor
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
WO2022019998A1
(en)
|
2020-07-20 |
2022-01-27 |
Arog Pharmaceuticals, Inc. |
Crystal forms of crenolanib and methods of use thereof
|
WO2022047093A1
(en)
|
2020-08-28 |
2022-03-03 |
Incyte Corporation |
Vinyl imidazole compounds as inhibitors of kras
|
US20230364095A1
(en)
|
2020-09-16 |
2023-11-16 |
Incyte Corporation |
Topical treatment of vitiligo
|
WO2022072783A1
(en)
|
2020-10-02 |
2022-04-07 |
Incyte Corporation |
Bicyclic dione compounds as inhibitors of kras
|
KR20230118118A
(ko)
|
2020-12-08 |
2023-08-10 |
인사이트 코포레이션 |
백반증의 치료를 위한 jak1 경로 저해제
|
WO2022155941A1
(en)
|
2021-01-25 |
2022-07-28 |
Qilu Regor Therapeutics Inc. |
Cdk2 inhibitors
|
WO2022206888A1
(en)
|
2021-03-31 |
2022-10-06 |
Qilu Regor Therapeutics Inc. |
Cdk2 inhibitors and use thereof
|
JP2024513575A
(ja)
|
2021-04-12 |
2024-03-26 |
インサイト・コーポレイション |
Fgfr阻害剤及びネクチン-4標的化剤を含む併用療法
|
AR126101A1
(es)
|
2021-06-09 |
2023-09-13 |
Incyte Corp |
Heterociclos tricíclicos como inhibidores de fgfr
|
US11939331B2
(en)
|
2021-06-09 |
2024-03-26 |
Incyte Corporation |
Tricyclic heterocycles as FGFR inhibitors
|
US20230056631A1
(en)
|
2021-07-07 |
2023-02-23 |
Incyte Corporation |
Tricyclic compounds as inhibitors of kras
|
US20230114765A1
(en)
|
2021-07-14 |
2023-04-13 |
Incyte Corporation |
Tricyclic compounds as inhibitors of kras
|
CA3229855A1
(en)
|
2021-08-31 |
2023-03-09 |
Incyte Corporation |
Naphthyridine compounds as inhibitors of kras
|
US20230151005A1
(en)
|
2021-09-21 |
2023-05-18 |
Incyte Corporation |
Hetero-tricyclic compounds as inhibitors of kras
|
WO2023056421A1
(en)
|
2021-10-01 |
2023-04-06 |
Incyte Corporation |
Pyrazoloquinoline kras inhibitors
|
CA3235146A1
(en)
|
2021-10-14 |
2023-04-20 |
Incyte Corporation |
Quinoline compounds as inhibitors of kras
|
WO2023081923A1
(en)
|
2021-11-08 |
2023-05-11 |
Frequency Therapeutics, Inc. |
Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
|
US20230226040A1
(en)
|
2021-11-22 |
2023-07-20 |
Incyte Corporation |
Combination therapy comprising an fgfr inhibitor and a kras inhibitor
|
WO2023102184A1
(en)
|
2021-12-03 |
2023-06-08 |
Incyte Corporation |
Bicyclic amine compounds as cdk12 inhibitors
|
US20230183251A1
(en)
|
2021-12-10 |
2023-06-15 |
Incyte Corporation |
Bicyclic amines as cdk12 inhibitors
|
US20230192722A1
(en)
|
2021-12-22 |
2023-06-22 |
Incyte Corporation |
Salts and solid forms of an fgfr inhibitor and processes of preparing thereof
|
WO2023168686A1
(en)
|
2022-03-11 |
2023-09-14 |
Qilu Regor Therapeutics Inc. |
Substituted cyclopentanes as cdk2 inhibitors
|
TW202341982A
(zh)
|
2021-12-24 |
2023-11-01 |
大陸商上海齊魯銳格醫藥研發有限公司 |
Cdk2抑制劑及其用途
|
US20230279004A1
(en)
|
2022-03-07 |
2023-09-07 |
Incyte Corporation |
Solid forms, salts, and processes of preparation of a cdk2 inhibitor
|
US20230399331A1
(en)
|
2022-06-14 |
2023-12-14 |
Incyte Corporation |
Solid forms of jak inhibitor and process of preparing the same
|
CN114853784B
(zh)
*
|
2022-06-16 |
2023-09-05 |
贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) |
一种十字孢碱类化合物及其制备方法与应用
|
WO2023250430A1
(en)
|
2022-06-22 |
2023-12-28 |
Incyte Corporation |
Bicyclic amine cdk12 inhibitors
|
WO2024015731A1
(en)
|
2022-07-11 |
2024-01-18 |
Incyte Corporation |
Fused tricyclic compounds as inhibitors of kras g12v mutants
|
US20240058343A1
(en)
|
2022-08-05 |
2024-02-22 |
Incyte Corporation |
Treatment of urticaria using jak inhibitors
|